
Digital development at Denmark's largest pharmaceutical company Novo Nordisk is powering ahead.
In recent months, the firm has relaunched its two smart insulin pens in Sweden and launched a phase III trial with its own phone app called Doseguide. Novo Nordisk also tells MedWatch that the company is working towards introducting a digital therapeutic solution to assist patients taking insulin treatments.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app